COMMUNIQUÉS West-GlobeNewswire

-
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
07/05/2024 -
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
07/05/2024 -
Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
07/05/2024 -
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
07/05/2024 -
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
07/05/2024 -
Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDO
07/05/2024 -
Amolyt Pharma dévoile les abstracts acceptés pour présentation aux congrès de la GRS, de l'ECE et de l'ENDO
07/05/2024 -
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
07/05/2024 -
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
07/05/2024 -
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
07/05/2024 -
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
07/05/2024 -
Reflect Scientific Inc. Announces Second Quarter Sale of Groundbreaking Aerospace Manufacturing Solution
07/05/2024 -
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
07/05/2024 -
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
07/05/2024 -
4DMT to Participate in Upcoming Investor Conference
07/05/2024 -
Cogent Biosciences Reports First Quarter 2024 Financial Results
07/05/2024 -
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
07/05/2024 -
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
07/05/2024 -
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
07/05/2024
Pages